Roche Holding AG represents a strong commitment to innovation, integrity, and patient-centered healthcare. As one of the leading pharmaceutical and diagnostics companies globally, Roche focuses on developing groundbreaking therapeutic solutions and advanced diagnostic tools. The company's core values include scientific excellence, teamwork, and a passion for improving patients' lives. With a dedication to personalized healthcare and a long-standing tradition of ethical conduct, Roche strives to make a positive impact on society. Through continuous research and development efforts, Roche aims to provide effective treatments and diagnostic solutions for various diseases, ultimately contributing to the advancement of healthcare worldwide.

Roche Holding AG is primarily present in multiple countries and regions worldwide. The company has a significant presence in Switzerland, where it is headquartered. In addition, Roche Holding AG has a strong presence in the United States, Germany, Japan, China, and other key markets around the globe. With its global reach, Roche Holding AG has established itself as a leading biotechnology and pharmaceutical firm, delivering innovative healthcare solutions to diverse populations across various countries and regions.

Roche Holding AG has achieved numerous significant milestones throughout its history. Established in 1896, it has become a leader in the pharmaceutical and diagnostics industry. Some notable milestones include the development of groundbreaking drugs such as Valium, Tamiflu, and Herceptin, which have revolutionized the treatment of various diseases. Roche Holding AG has also been at the forefront of advancing precision medicine with its innovative therapies, such as Avastin and Rituxan. The company's commitment to research and development has resulted in a diverse product portfolio, contributing to its global success and recognition as a leading healthcare company.

Roche Holding AG, a renowned global healthcare company, has a rich history and background. Established in 1896 in Switzerland, Roche has become a leader in pharmaceuticals and diagnostics. With major breakthroughs in various therapeutic areas, Roche has contributed significantly to enhancing patient care and improving outcomes. The company's commitment to innovation and research has led to the development of groundbreaking medicines and diagnostic tests, addressing medical needs worldwide. Roche's diverse portfolio includes a range of medicines for oncology, immunology, neuroscience, infectious diseases, and more. With a strong focus on personalized healthcare, Roche continues to shape the future of medicine and positively impact patients' lives globally.

The main competitors of Roche Holding AG in the market include Novartis AG, Johnson & Johnson, and Pfizer Inc.

Roche Holding AG is primarily active in the pharmaceutical and healthcare industries.

The business model of Roche Holding AG is focused on pharmaceuticals and diagnostics. Roche is a global healthcare company that aims to improve people's lives by providing innovative medical solutions. With its innovative research and development capabilities, Roche develops and sells a wide range of pharmaceutical and biotechnology products. The company's diagnostics division specializes in developing and manufacturing diagnostic tests and systems to support personalized healthcare. Through ongoing investments in research, Roche strives to address unmet medical needs and improve patient outcomes. As a leading player in the healthcare industry, Roche is committed to delivering high-quality and effective healthcare solutions to individuals worldwide.

Roche Holding의 P/E 비율은 14.14입니다.

Roche Holding의 P/S 비율은 3.67입니다.

Roche Holding에 대한 AlleAktien 품질 점수는 6/10입니다.

예상되는 Roche Holding 매출은 65.63 조. CHF입니다.

예상되는 Roche Holding 이익은 17.05 조. CHF입니다.

The Roche Holding AG is a Swiss pharmaceutical company based in Basel. The company operates worldwide and specializes in the development and production of medications, as well as diagnostic and laboratory equipment. Roche is divided into two core business areas: pharmaceuticals and diagnostics. In the pharmaceuticals area, Roche specializes in the development of medications and therapies in the fields of oncology, immunology, virology, metabolic disorders, and CNS diseases. Some of Roche's most well-known medications include Avastin, Herceptin, MabThera, and Rituxan. These medications are used for the treatment of cancer and other serious diseases. In the diagnostics area, Roche holds a leading position in the field of in-vitro diagnostics (IVD) and offers tests and test systems for a variety of diseases. Roche is the world's largest provider of IVD tests and offers tests for the diagnosis of cancer, infectious diseases, blood clots, and cardiovascular diseases, among others. The company has also developed instruments and software to improve laboratory efficiency and accuracy. Roche has extensive expertise in medicine and the life sciences, and the company is committed to developing innovative therapies and solutions that improve healthcare. Roche's focus on research and development is evident - the company invests more than 11 billion Swiss francs annually in research and development projects and collaborates with leading research institutions. Roche's business model is focused on creating value for patients, customers, employees, and investors. The company places great importance on innovation, patient orientation, and sustainability, and is committed to protecting the environment and reducing CO2 emissions. Roche also pursues a targeted acquisition strategy to strengthen its presence in selected markets and acquire new technologies. In 2018, Roche acquired the US company Foundation Medicine, a leading company in the field of personalized oncology and diagnostics. With this acquisition, Roche strengthened its presence in the field of personalized medicine. Overall, Roche's business model is focused on long-term growth by developing innovative medications and diagnostic tests to meet the unmet need for healthcare services. The company is committed to improving healthcare worldwide and strives to ensure that patients can be treated faster and more effectively, and that diseases can be identified as early as possible.

Roche Holding은(는) 연간 1번의 배당을 통해 9.3 CHF의 배당금을 지급합니다.

Roche Holding는 연간 1번의 배당금을 지급합니다.

Roche Holding의 ISIN은 CH0012032048입니다.

Roche Holding의 WKN은 855167입니다.

Roche Holding의 티커는 ROG.SW입니다.

지난 12개월 동안 Roche Holding은(는) 9.5 CHF 의 배당금을 지급했습니다. 이는 약 3.17 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Roche Holding은(는) 11.28 CHF의 배당금을 지급할 것으로 예상됩니다.

Roche Holding의 현재 배당 수익률은 3.17 %입니다.

Roche Holding은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Roche Holding은(는) 지난 38년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 11.28 CHF의 배당금이 예상됩니다. 이는 배당수익률 3.76 %에 해당합니다.

Roche Holding은 '건강' 섹터에 속합니다.

Roche Holding의 마지막 배당금을 9.7 CHF만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Roche Holding는 9.5 CHF를 배당금으로 지급했습니다.

Roche Holding의 배당금은 CHF에 지급됩니다.